{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:44:42Z","timestamp":1794462282522,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    TAK-653 is a novel AMPA receptor positive allosteric modulator in clinical development for the treatment of major depressive disorder (MDD). This study aimed to measure the functional pharmacodynamic central nervous system (CNS) effects of TAK-653. A randomised, double-blind, placebo-controlled, three-way crossover (placebo, TAK-653 0.5\u2009mg and 6\u2009mg) study with 24 healthy volunteers was performed. NeuroCart tests consisting of body sway (BS), saccadic peak velocity (SPV), smooth pursuit eye movements (SP), adaptive tracking (AT), Bowdle and Bond and Lader Visual Analogue Scales (B-VAS and BL-VAS) and Stroop test were performed pre-dose and 3.5 and 4\u2009h post-dose. Data were analysed using a mixed model analysis of covariance with baseline as covariate. It was found that TAK-653 did not affect BS and subjective drug effects as measured by B-VAS and BL-VAS at either dose level. TAK-653 0.5\u2009mg increased SPV (degrees\/second) (19.49 [5.98, 32.99],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02) and affected Stroop difference in reaction time between correct congruent and correct incongruent answers and number of correct responses in incongruent trials (22.0 [4.0, 40.0],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.05 and \u22120.3 [\u22120.5, \u22120.1],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02, respectively). TAK-653 6\u2009mg improved AT (%) (1.68 [0.51, 2.84],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02) and increased SPV (degrees\/s) (15.40 [1.91, 28.90],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.06) and SP (%) (2.32 [0.37, 4.27],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.05). Based on these findings it can be concluded that TAK-653 demonstrated a psychostimulant-like pharmacodynamic profile on the NeuroCart consistent with previously reported increase of cortical excitability following Transcranial Magnetic Stimulation (TMS) of the human motor cortex.\n                  <\/jats:p>","DOI":"10.1038\/s41398-022-02148-w","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T08:03:43Z","timestamp":1664006623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-0708","authenticated-orcid":false,"given":"Francis","family":"Dijkstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4433-7150","authenticated-orcid":false,"given":"Derek","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Asgharnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-0157","authenticated-orcid":false,"given":"Rob","family":"Zuiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop","family":"van Gerven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabri\u00ebl","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"key":"2148_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"2148_CR2","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392.","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134\u201342. https:\/\/doi.org\/10.1176\/appi.ajp.2013.13030392.","journal-title":"Am J Psychiatry"},{"key":"2148_CR3","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856.","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856\u201364. https:\/\/doi.org\/10.1001\/archpsyc.63.8.856.","journal-title":"Arch Gen Psychiatry"},{"key":"2148_CR4","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1097\/WNR.0000000000001131","volume":"29","author":"G Collo","year":"2018","unstructured":"Collo G, Cavalleri L, Chiamulera C, Merlo Pich E. (2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans. Neuroreport. 2018;29:1425\u201330. https:\/\/doi.org\/10.1097\/WNR.0000000000001131.","journal-title":"Neuroreport"},{"key":"2148_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998.","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481\u20136. https:\/\/doi.org\/10.1038\/nature17998.","journal-title":"Nature"},{"key":"2148_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287.","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959\u201364. https:\/\/doi.org\/10.1126\/science.1190287.","journal-title":"Science"},{"key":"2148_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neuropharm.2019.04.019.","volume":"153","author":"CL Shaffer","year":"2019","unstructured":"Shaffer CL, Dutra JK, Tseng WC, Weber ML, Bogart LJ, Hales K, et al. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine. Neuropharmacology. 2019;153:73\u201381. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.04.019.","journal-title":"Neuropharmacology"},{"key":"2148_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.08.044.","volume":"62","author":"RS Duman","year":"2012","unstructured":"Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology. 2012;62:35\u201341. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.08.044.","journal-title":"Neuropharmacology"},{"key":"2148_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028.","volume":"63","author":"S Maeng","year":"2008","unstructured":"Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349\u201352. https:\/\/doi.org\/10.1016\/j.biopsych.2007.05.028.","journal-title":"Biol Psychiatry"},{"key":"2148_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/epi.14082.","volume":"59","author":"A Leo","year":"2018","unstructured":"Leo A, Giovannini G, Russo E, Meletti S. The role of AMPA receptors and their antagonists in status epilepticus. Epilepsia. 2018;59:1098\u2013108. https:\/\/doi.org\/10.1111\/epi.14082.","journal-title":"Epilepsia"},{"key":"2148_CR11","first-page":"S157","volume":"43","author":"XU Asgharnejad","year":"2018","unstructured":"Asgharnejad XU, Dong, Iadevaia, Dorner A, Murthy V, Ratti E, et al. Pharmacokinetic and pharmacodynamic properties of the investigational AMPA receptor positive allosteric modulator TAK-653 after single and multiple rising doses in healthy volunteers. Neuropsychopharmacology 2018;43:S157.","journal-title":"Neuropsychopharmacology"},{"key":"2148_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev-pharmtox-011613-135918.","volume":"55","author":"AF Cohen","year":"2015","unstructured":"Cohen AF, Burggraaf J, van Gerven JM, Moerland M, Groeneveld GJ. The use of biomarkers in human pharmacology (Phase I) studies. Annu Rev Pharm Toxicol. 2015;55:55\u201374. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011613-135918.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"2148_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.drudis.2011.12.020.","volume":"17","author":"P Morgan","year":"2012","unstructured":"Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012;17:419\u201324. https:\/\/doi.org\/10.1016\/j.drudis.2011.12.020.","journal-title":"Drug Discov Today"},{"key":"2148_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ddtec.2016.07.004.","volume":"20","author":"GJ Groeneveld","year":"2016","unstructured":"Groeneveld GJ, Hay JL, Van Gerven JM. Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery. Drug Discov Today Technol 2016;20:27\u201334. https:\/\/doi.org\/10.1016\/j.ddtec.2016.07.004.","journal-title":"Drug Discov Today Technol"},{"key":"2148_CR15","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1177\/0269881120914206.","volume":"34","author":"K Recourt","year":"2020","unstructured":"Recourt K, van der Aart J, Jacobs G, de Kam M, Drevets W, van Nueten L, et al. Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. J Psychopharmacol. 2020;34:1030\u201342. https:\/\/doi.org\/10.1177\/0269881120914206.","journal-title":"J Psychopharmacol"},{"key":"2148_CR16","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/bcp.13204.","volume":"83","author":"X Chen","year":"2017","unstructured":"Chen X, Broeyer F, de Kam M, Baas J, Cohen A, van Gerven J. Pharmacodynamic response profiles of anxiolytic and sedative drugs. Br J Clin Pharm. 2017;83:1028\u201338. https:\/\/doi.org\/10.1111\/bcp.13204.","journal-title":"Br J Clin Pharm"},{"key":"2148_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/JCP.0000000000000251","volume":"35","author":"X Chen","year":"2015","unstructured":"Chen X, Jacobs G, de Kam ML, Jaeger J, Lappalainen J, Maruff P, et al. AZD6280, a novel partial \u03b3-aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers. J Clin Psychopharmacol. 2015;35:22\u201333. https:\/\/doi.org\/10.1097\/JCP.0000000000000251.","journal-title":"J Clin Psychopharmacol"},{"key":"2148_CR18","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/bcp.12413.","volume":"78","author":"X Chen","year":"2014","unstructured":"Chen X, Jacobs G, de Kam, Jaeger J, Lappalainen J, Maruff P, et al. The central nervous system effects of the partial GABA-Aalpha2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males. Br J Clin Pharm. 2014;78:1298\u2013314. https:\/\/doi.org\/10.1111\/bcp.12413.","journal-title":"Br J Clin Pharm"},{"key":"2148_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0269881106072343","volume":"21","author":"SL de Haas","year":"2006","unstructured":"de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, et al. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA \u03b12,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol. 2006;21:374\u201383. https:\/\/doi.org\/10.1177\/0269881106072343","journal-title":"J Psychopharmacol"},{"key":"2148_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/0269881108092595.","volume":"23","author":"SL de Haas","year":"2009","unstructured":"de Haas SL, Franson KL, Schmitt JA, Cohen AF, Fau JB, Dubruc C, et al. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol. 2009;23:625\u201332. https:\/\/doi.org\/10.1177\/0269881108092595.","journal-title":"J Psychopharmacol"},{"key":"2148_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/0269881107082108.","volume":"22","author":"SL de Haas","year":"2008","unstructured":"de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, et al. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol. 2008;22:24\u201332. https:\/\/doi.org\/10.1177\/0269881107082108.","journal-title":"J Psychopharmacol"},{"key":"2148_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01451-2.","volume":"11","author":"P O\u2019Donnell","year":"2021","unstructured":"O\u2019Donnell P, Dijkstra FM, Damar U, Quanhong L, de Goede A, Xu L, et al. Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation. Transl Psychiatry. 2021;11:325 https:\/\/doi.org\/10.1038\/s41398-021-01451-2.","journal-title":"Transl Psychiatry"},{"key":"2148_CR23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704.","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Posner, Brent DA, Yershova KV, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266\u201377. https:\/\/doi.org\/10.1176\/appi.ajp.2011.10111704.","journal-title":"Am J Psychiatry"},{"key":"2148_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/clpt.1991.122","volume":"50","author":"AL van Steveninck","year":"1991","unstructured":"van Steveninck AL, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharm Ther. 1991;50:172\u201380.","journal-title":"Clin Pharm Ther"},{"key":"2148_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/026988119901300102.","volume":"13","author":"AL van Steveninck","year":"1999","unstructured":"van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol. 1999;13:10\u201317. https:\/\/doi.org\/10.1177\/026988119901300102.","journal-title":"J Psychopharmacol"},{"key":"2148_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1365-2125.1997.t01-1-00580.x.","volume":"44","author":"AL van Steveninck","year":"1997","unstructured":"van Steveninck AL, Wallnofer AE, Schoemaker RC, Pieters MS, Danhof M, van Gerven JMA, et al. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharm. 1997;44:267\u201375. https:\/\/doi.org\/10.1046\/j.1365-2125.1997.t01-1-00580.x.","journal-title":"Br J Clin Pharm"},{"key":"2148_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/bf02244655.","volume":"110","author":"AL van Steveninck","year":"1993","unstructured":"van Steveninck AL, Gieschke R, Schoemaker HC, Pieters MS, Kroon JM, Breimer DD, et al. Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. Psychopharmacology 1993;110:471\u20138. https:\/\/doi.org\/10.1007\/bf02244655.","journal-title":"Psychopharmacology"},{"key":"2148_CR28","first-page":"27p","volume":"218","author":"BM Wright","year":"1971","unstructured":"Wright BM. A simple mechanical ataxia-meter. J Physiol. 1971;218:27p\u201328p.","journal-title":"J Physiol"},{"key":"2148_CR29","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/bcp.13885.","volume":"85","author":"AC Baakman","year":"2019","unstructured":"Baakman AC, Zuiker R, van Gerven JMA, Gross N, Yang R, Fetell M, et al. Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers. Br J Clin Pharm. 2019;85:970\u201385. https:\/\/doi.org\/10.1111\/bcp.13885.","journal-title":"Br J Clin Pharm"},{"key":"2148_CR30","unstructured":"Klein RH, Minimally invasive methodology for pharmacological research involving children. Published online 2013."},{"key":"2148_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.1365-2125.1996.38514.x.","volume":"41","author":"AL van Steveninck","year":"1996","unstructured":"van Steveninck AL, Gieschke R, Schoemaker RC, Roncari G, Tuk B, Pieters MS, et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharm. 1996;41:565\u201373. https:\/\/doi.org\/10.1046\/j.1365-2125.1996.38514.x.","journal-title":"Br J Clin Pharm"},{"key":"2148_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1365-2125.1983.tb01495.x.","volume":"15","author":"PR Bittencourt","year":"1983","unstructured":"Bittencourt PR, Wade P, Smith AT, Richens A. Benzodiazepines impair smooth pursuit eye movements. Br J Clin Pharm. 1983;15:259\u201362. https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb01495.x.","journal-title":"Br J Clin Pharm"},{"key":"2148_CR33","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1212\/wnl.25.11.1065.","volume":"25","author":"RW Baloh","year":"1975","unstructured":"Baloh RW, Sills AW, Kumley WE, Honrubia V. Quantitative measurement of saccade amplitude, duration, and velocity. Neurology. 1975;25:1065\u201370. https:\/\/doi.org\/10.1212\/wnl.25.11.1065.","journal-title":"Neurology"},{"key":"2148_CR34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/0269881116668593.","volume":"31","author":"MM Wilhelmus","year":"2017","unstructured":"Wilhelmus MM, Hay JL, Zuiker RG, Okkerse P, Perdrieu C, Sauser J, et al. Effects of a single, oral 60 mg caffeine dose on attention in healthy adult subjects. J Psychopharmacol. 2017;31:222\u201332. https:\/\/doi.org\/10.1177\/0269881116668593.","journal-title":"J Psychopharmacol"},{"key":"2148_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2001.01308.x","volume":"51","author":"SJ de Visser","year":"2001","unstructured":"de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharm. 2001;51:119\u201332.","journal-title":"Br J Clin Pharm"},{"key":"2148_CR36","doi-asserted-by":"crossref","unstructured":"Borland RG, Nicholson AN. Visual motor co-ordination and dynamic visual acuity. Br J Clin Pharm. 1984;18:69S\u201372S. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6525331.","DOI":"10.1111\/j.1365-2125.1984.tb02583.x"},{"key":"2148_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1037\/h0054651.","volume":"18","author":"JR Stroop","year":"1935","unstructured":"Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643\u201362. https:\/\/doi.org\/10.1037\/h0054651.","journal-title":"J Exp Psychol"},{"key":"2148_CR38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1365-2125.1986.tb05229.x.","volume":"21","author":"AN Griffiths","year":"1986","unstructured":"Griffiths AN, Jones DM, Richens A. Zopiclone produces effects on human performance similar to flurazepam, lormetazepam and triazolam. Br J Clin Pharm. 1986;21:647\u201353. https:\/\/doi.org\/10.1111\/j.1365-2125.1986.tb05229.x.","journal-title":"Br J Clin Pharm"},{"key":"2148_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/jnnp.2004.038729.","volume":"76","author":"NI Bohnen","year":"2005","unstructured":"Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Koeppe RA, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2005;76:315\u20139. https:\/\/doi.org\/10.1136\/jnnp.2004.038729.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2148_CR40","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/alcalc\/agm073.","volume":"42","author":"AK Rose","year":"2007","unstructured":"Rose AK, Duka T. The influence of alcohol on basic motoric and cognitive disinhibition. Alcohol Alcohol. 2007;42:544\u201351. https:\/\/doi.org\/10.1093\/alcalc\/agm073.","journal-title":"Alcohol Alcohol"},{"key":"2148_CR41","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1177\/0269881109358200.","volume":"24","author":"M Liem-Moolenaar","year":"2010","unstructured":"Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol. 2010;24:1697\u2013708. https:\/\/doi.org\/10.1177\/0269881109358200.","journal-title":"J Psychopharmacol"},{"key":"2148_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0028-3908(71)90039-6","volume":"10","author":"H Norris","year":"1971","unstructured":"Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 1971;10:181\u201391.","journal-title":"Neuropharmacology"},{"key":"2148_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/clpt.2010.19.","volume":"87","author":"P Hoever","year":"2010","unstructured":"Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharm Ther. 2010;87:593\u2013600. https:\/\/doi.org\/10.1038\/clpt.2010.19.","journal-title":"Clin Pharm Ther"},{"key":"2148_CR44","unstructured":"Visser SJ. de, A question-based approach to drug development. Leiden (The Netherlands): Leiden University. 2003."},{"key":"2148_CR45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00000542-199801000-00015.","volume":"88","author":"AT Bowdle","year":"1998","unstructured":"Bowdle AT, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in healthy volunteers relationship to steady-state plasma concentrations. Anesthesiology. 1998;88:82\u201388. https:\/\/doi.org\/10.1097\/00000542-199801000-00015.","journal-title":"Anesthesiology"},{"key":"2148_CR46","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/0269881108089581.","volume":"22","author":"L Zuurman","year":"2008","unstructured":"Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JCME, et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol. 2008;22:707\u201316. https:\/\/doi.org\/10.1177\/0269881108089581.","journal-title":"J Psychopharmacol"},{"key":"2148_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0010-0277(94)90068-x.","volume":"53","author":"CL Gerstadt","year":"1994","unstructured":"Gerstadt CL, Hong YJ, Diamond A. The relationship between cognition and action: performance of children 3 1\/2-7 years old on a Stroop-like day-night test. Cognition 1994;53:129\u201353. https:\/\/doi.org\/10.1016\/0010-0277(94)90068-x.","journal-title":"Cognition"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02148-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02148-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02148-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T12:26:04Z","timestamp":1701087964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02148-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2148"],"URL":"https:\/\/doi.org\/10.1038\/s41398-022-02148-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1756755\/v1","asserted-by":"object"}]},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,24]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PO, DB, MA and LR are all (former) employees of Takeda Pharmaceutical Company, Ltd and own stock or stock options. The other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Medical Ethics Committee foundation Beoordeling Ethiek Biomedisch Onderzoek (BEBO) and was registered at ClinicalTrials.gov (NCT03792672). The study was performed according to International Conference on Harmonisation Good Clinical Practice guidelines, as laid down in the Declaration of Helsinki and its latest amendments. Written informed consent was obtained from all participants before any study-related activities were performed. The study was performed at the Centre for Human Drug Research, Leiden, the Netherlands from 23 January 2019 to 18 June 2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"408"}}